Vanderbilt University Medical Center has entered into a strategic research agreement with Celgene Corporation, a biopharmaceutical company based in Summit, New Jersey.

Ten members of Vanderbilt University’s faculty have been elected fellows of the American Association for the Advancement of Science.

Two physician-scientist leaders at Vanderbilt University Medical Center were honored last week with newly created awards for helping to build and nurture Vanderbilt’s vibrant culture of clinical and translational research.

The Vanderbilt Institute for Clinical and Translational Research (VICTR) is partnering with a public charity, Cures Within Reach, to encourage “rediscovery research,” the “repurposing” of already approved medical treatments to other conditions or diseases for which there are no “universally” effective therapies.

Tina Hartert, M.D., MPH, professor of Medicine in the Division of Allergy, Pulmonary and Critical Care Medicine, has been named assistant vice chancellor for Translational Science.

VUMC researchers have reported promising results in using oral antimycobacterial therapy to treat chronic cutaneous sarcoidosis, considered by clinicians a difficult illness to effectively control.

"Vanderbilt's Nobel Prize," the Earl Sutherland Prize for achievement in research, was awarded to John Gore at the Fall Faculty Assembly, while Gordon Bernard received the Thomas Jefferson Award for distinguished service to Vanderbilt.